|1.||Higuchi, Keiichi: 14 articles (03/2015 - 09/2002)|
|2.||Mori, Masayuki: 12 articles (03/2015 - 09/2002)|
|3.||Fu, Xiaoying: 10 articles (08/2011 - 09/2002)|
|4.||Sawashita, Jinko: 9 articles (03/2015 - 03/2006)|
|5.||Zhang, Beiru: 7 articles (02/2015 - 07/2007)|
|6.||Naiki, Hironobu: 6 articles (02/2015 - 05/2004)|
|7.||Blanco-Vaca, Francisco: 6 articles (12/2005 - 04/2002)|
|8.||Qian, Jinze: 5 articles (03/2015 - 07/2007)|
|9.||Chan, Dick C: 5 articles (06/2012 - 07/2006)|
|10.||Watts, Gerald F: 5 articles (06/2012 - 07/2006)|
11/01/2001 - "Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein."
02/01/2013 - "We aimed to examine whether apo A-II plays any role in atherogenesis and, if so, to elucidate the mechanism involved. "
02/01/2013 - "Human apolipoprotein A-II protects against diet-induced atherosclerosis in transgenic rabbits."
06/01/2012 - "There is no evidence, however, that selective therapeutic modification of apoA-II impacts on atherosclerosis and clinical outcomes. "
02/01/2006 - "Significant, positive associations were found between apoA-II and C-III (r=0.883, P<0.001) and between apoA-II and atherosclerosis (r=0.68, P<0.001). "
|2.||Coronary Artery Disease (Coronary Atherosclerosis)
06/01/1993 - "Apolipoprotein A-II levels and coronary artery disease in subjects with and without diabetes: a study with use of a specific radioimmunoassay for apolipoprotein A-II."
08/01/2008 - "The apolipoprotein AII rs5082 variant is associated with reduced risk of coronary artery disease in an Australian male population."
10/30/2007 - "Apolipoprotein A-II is inversely associated with risk of future coronary artery disease."
06/01/1993 - "In subjects with diabetes, however, apo A-II levels are similar in the presence or absence of coronary artery disease."
06/01/1993 - "After adjustments were made for age and sex, however, apo A-II levels were no longer significantly different between subjects with diabetes who had and those who did not have coronary artery disease. "
03/18/2014 - "Together, experimental and bioinformatics studies explain why the C-terminal extension in human apoA-II causes amyloidosis and why, unlike murine apoA-II, human apoA-II normally does not cause amyloidosis despite its unusually high sequence propensity for β-aggregation. "
02/24/2015 - "Here, we demonstrate that congenic mouse strains carrying type F apoA-II (APOA2F) protein, which contains four amino acid substitutions in the amyloidogenic regions of APOA2C, were absolutely resistant to amyloidosis, even after induction of amyloidosis by injection of AApoAII. "
02/24/2015 - "Mouse strains carrying type C apoA-II (APOA2C) protein exhibit a high incidence of severe systemic amyloidosis. "
03/18/2014 - "C-terminal extension in human apoA-II or point substitutions in murine apoA-II cause amyloidosis. "
03/18/2014 - "Hot spots in apolipoprotein A-II misfolding and amyloidosis in mice and men."
04/01/2003 - "More clinical studies are necessary to clarify the role of apolipoprotein A-II in well-characterized subsets of patients and in the insulin resistance syndrome."
03/01/2001 - "Studies with apolipoprotein A-II transgenic mice indicate a role for HDLs in adiposity and insulin resistance."
12/01/2004 - "Mechanisms mediating insulin resistance in transgenic mice overexpressing mouse apolipoprotein A-II."
04/01/2003 - "Apolipoprotein A-II: beyond genetic associations with lipid disorders and insulin resistance."
07/01/2002 - "Evaluation of apolipoprotein A-II as a positional candidate gene for familial Type II diabetes, altered lipid concentrations, and insulin resistance."
12/01/2006 - "Postprandial hypertriglyceridemia and low plasma HDL levels, which are principal features of the metabolic syndrome, are displayed by transgenic mice expressing human apolipoprotein A-II (hapoA-II). "
04/30/2002 - "On the mechanisms by which human apolipoprotein A-II gene variability relates to hypertriglyceridemia."
02/01/1998 - "Association between apolipoprotein A2 MspI polymorphism and hypertriglyceridemia in Koreans."
09/01/2007 - "This finding may partially explain the role of Apo A-II in lipid metabolism and can identify a population with a decreased risk of cardiovascular disease, as corresponds to the lower level of postprandial hypertriglyceridemia."
04/01/2002 - "Overexpression of human apolipoprotein A-II (hapo A-II) in transgenic mice (hAIItg mice) induced marked hypertriglyceridemia and low levels of plasma high density lipoprotein (HDL) with a high hapo A-II content. "
|1.||Apolipoprotein A-I (Apolipoprotein A1)
|3.||Proteins (Proteins, Gene)
|4.||Apolipoproteins E (ApoE)
|5.||Messenger RNA (mRNA)
|10.||Apolipoprotein A-II (Apolipoprotein A2)
|1.||Hormone Replacement Therapy (Therapy, Hormone Replacement)
|2.||Fat-Restricted Diet (Diet, Fat Restricted)